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Diffusion-weighted magnetic resonance imaging (DWI) enables non-invasive, quantitative
staging of prostate cancer via measurement of the apparent diffusion coefficient (ADC)
of water within tissues. In cancer, more advanced disease is often characterized by
higher cellular density (cellularity), which is generally accepted to correspond to a lower
measured ADC. A quantitative relationship between tissue structure and in vivomeasure-
ments of ADC has yet to be determined for prostate cancer. In this study, we establish
a theoretical framework for relating ADC measurements with tissue cellularity and the
proportion of space occupied by prostate lumina, both of which are estimated through
automatic image processing of whole-slide digital histology samples taken from a cohort
of six healthy mice and nine transgenic adenocarcinoma of the mouse prostate (TRAMP)
mice. We demonstrate that a significant inverse relationship exists between ADC and
tissue cellularity that is well characterized by our model, and that a decrease of the luminal
space within the prostate is associated with a decrease in ADC and more aggressive
tumor subtype. The parameters estimated from our model in this mouse cohort predict
the diffusion coefficient of water within the prostate-tissue to be 2.1810 3 mm2/s (95%
CI: 1.90, 2.55). This value is significantly lower than the diffusion coefficient of free water
at body temperature suggesting that the presence of organelles and macromolecules
within tissues can drastically hinder the randommotion of water molecules within prostate
tissue. We validate the assumptions made by our model using novel in silico analysis
of whole-slide histology to provide the simulated ADC (sADC); this is demonstrated
to have a significant positive correlation with in vivo measured ADC (r2=0.55) in our
mouse population. The estimation of the structural properties of prostate tissue is vital for
predicting and staging cancer aggressiveness, but prostate tissue biopsies are painful,
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invasive, and are prone to complications such as sepsis. The developments made in this
study provide the possibility of estimating the structural properties of prostate tissue via
non-invasive virtual biopsies from MRI, minimizing the need for multiple tissue biopsies
and allowing sequential measurements to be made for prostate cancer monitoring.
Keywords: diffusion-weighted imaging, cellularity, whole-slide histology, mouse models of cancer, prostate cancer
1. INTRODUCTION
Affecting one in eight during their lifetime, prostate cancer (PCa)
remains the most common cause of cancer in men (1). Although
patient prognosis has continued to improve, 5-year relative sur-
vival is strongly correlated with cancer stage at diagnosis (1). A
recent European-wide study has demonstrated preliminary evi-
dence that prostate cancer screening can improve outcomes for
patients and prolong life where cancer is detected at an earlier
stage (2). This provides options for radical treatment such as
radiotherapy or prostatectomy, or non-interventional strategies
such as active surveillance and watchful waiting (3). The useful-
ness of PCa screening, however, remains controversial; the most
common screening tool, measurement of prostate-specific anti-
gen (PSA) serum levels, is prone to overdiagnosis and overtreat-
ment in up to 50% of cases (2, 4–7). PSA levels can be high in
patients due to confounding processes including chronic prostati-
tis, benign prostatic hyperplasia, sexual activity, and old age (8),
causing false positive test results in 76% of men with an elevated
PSA level (9). Current guidelines in the United Kingdom, there-
fore, suggest that PSAmeasurements should only be performed in
men following informed patient consent and understanding of the
associated risks (10).
A recent study has shown that multiparametric magnetic res-
onance imaging (mpMRI) offers high sensitivity for detecting
prostate cancer and could be used to triage men for prostate
biopsy (11). Furthermore, MRI-targeted biopsies may minimize
the number of biopsies required from each patient and reduce the
risk of sepsis and other biopsy-related side effects (12). Reporting
of mpMRI has recently been adopted into clinical practice for
PCa detection and demonstrated utility in the assessment of local
disease recurrence following radical treatments (13–20). Of par-
ticular importance is diffusion-weighted MRI (DWI) (14), which
offers in vivo measurement of the apparent diffusion coefficient
(ADC) to quantitatively identify prostate cancer (21): lower ADC
values appear to be associated with more biologically aggressive
cancers, providing a promising biomarker that is likely to impact
on active surveillance programmes (21–25). Unfortunately, the
biolophysical processes leading to differences in measured ADC
values are poorly understood. It is widely hypothesized that ADC
provides a surrogate marker of tissue cellularity (the number of
cells per unit volume) (26), but in the prostate, this simplistic
association does not account for the glandular structure of the
prostate, which is likely to have great impact on the measurement
of ADC in vivo (27–29).
In this study, we investigated the relationship between MRI-
derived ADC and the structural properties of prostate tissue
derived from whole-slide histology analysis of the transgenic
adenocarcinoma of the mouse prostate model (TRAMP). This
model recapitulates the progression of PCa observed in human
disease, with initial onset characterized by prostatic intraepithelial
neoplasia (PIN), leading to well-differentiated (WD) and then
poorly-differentiated (PD) disease (30–33). It has been recently
demonstrated that ADC can discriminate between these tissue
types (34). By quantifying the relationship between ADC, cel-
lularity, and the fraction of space occupied by prostate lumina
(the luminal fraction), we aim to demonstrate the broader util-
ity of ADC to inform on tissue characteristics of the entire
prostate. In addition, we introduce the simulated-ADC (sADC)
map, an in silico surrogate for in vivo ADC measurements cal-
culated through computer simulation of the motion of diffusing
water molecules within whole-slide histology images. The sADC
provides a unique opportunity to compare the diffusion charac-
teristics probed by MRI with parameters derived from histology
for each pixel and at high resolution.
2. THEORY
Amodel of MR-measured Apparent Diffusion Coefficient (ADC)
building on histological estimates of tissue cellularity was derived
using the principles of stereology (35). Wemodel theMR imaging
voxel to consist of two compartments: (i) an arrangement of
volumes within which no water diffusion occurs (one volume per
cell) bathed in (ii) a compartment of diffusing water. No water
exchange is permitted between these compartments.
A histology section is considered to be a finitely thin cross-
section of the MR imaging voxel with thickness z at position z,
in our case, along the MRI slice-encode direction (Figure 1).
Without loss of generality, we assume the MR imaging voxel and
histological pixel to be isotropic length L. The fractional area of
FIGURE 1 | An illustration of our biophysical model for water diffusion within
prostate tissue. Purple regions are impermeable to water diffusion that occurs
in the surrounding space. Histology provides higher resolution than MRI but is
limited to two-dimensional cross-sections of the tissue of interest (left). The
principle of stereology provides approximation of volume fraction diffusing
fluid, "3, from its cross-sectional area fraction, "2, estimated from histology
samples ("3 "2).
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diffusing fluid within a histology pixel is given by:
"2(z) = 1  An  C(z) (1)
where An represents the average cross-sectional area of non-
diffusing volumes (assumed to be constant over the thickness of
the MR-imaging voxel), and C(z) is the cellularity of the pixel
(number of cells per unit area). We approximate the MR voxel
as a piecewise summation of histological pixels in the z-direction
such that the volume of diffusing fluid within anMR voxel may be
approximated from its fractional area by:
Vf =
LZ
0
L2"2(z)dz = L3 
 
1  An  C

(2)
where C = 1L
R L
0 C(z)dz represents the average cellularity across
the imaging voxel thickness. In an ideal case, C could bemeasured
from a number of histological slices acquired over the thickness of
the imaging voxel, but here, we assume our measured cellularity
within a single histology image to be a good approximate (C  C).
We, therefore, conclude that the fractional area of diffusing fluid
derived from a cross-section of the MR voxel provides a good
estimate for its volume fraction:
"3 =
Vf
L3
 1  An  C = "2 (3)
To relate ADC to cellularity, we use a previously described power-
law (36, 37):
"3 =
r
ADC
D0
(4)
where D0 is the diffusion coefficient of fluidic component and  ,
the “tortuosity exponent,” represents the degree to which water
mobility is impeded by the presence of the non-diffusing vol-
umes, and is thought to depend on the structural shape of the
medium through which diffusion occurs (37). We validate a
two-dimensional version of this power-law through Monte-Carlo
simulations based on our histological specimens (Appendix B in
Supplementary Material).
Combining equations (3) and (4), we derive the following
relationship between MR-measured ADC and histology-derived
estimates of cellularity:
C = 1
An
0@1  ADCD0
 1
2
1A (5)
3. MATERIALS AND METHODS
3.1. Cellularity Calculation
Maps of cellularity (estimated as number of nuclei per unit area)
were calculated for each digitized slide according to the method
presented in Figure 2A: HES images were initially converted from
the RGB color space into the lightness channel (L) of the Lab color
space. An optimum threshold, topt, was then used to classify all
pixels with L< topt as positively stained nuclei, thus creating a
binary segmentation mask. The binary mask was subdivided into
a regular grid of square subregions, each measuring 500 500
pixels (0.115mm2 resolution), to represent the pixels in the final
cellularity map. Within each subregion, the ratio of the total area
covered by the mask to the mean nucleus cross-sectional area,
provided an estimate of nuclear count (the mean SE cross-
sectional area of nuclei was estimated to be 41.29 0.42 μm2
from 1,110 manually contoured nuclei from representative HES
histology images including all tissue types). The final cellularity
pixel value was thus derived by taking the ratio of the estimated
nucleus count to the total area in each subregion.
Our optimization strategy for determining segmentation
thresholds is outlined in Figure 2B. A representative region was
chosen from each digitized slide measuring 2,000 2,000 pixels
(0.46mm 0.46mm) and then subdivided into a regular grid
of the same dimensions used in cellularity calculation described
above. To provide a gold-standard cellularity estimate, a manual
nucleus count was performed in each subregion (Figure 2B, i).
FIGURE 2 | An illustration of our cellularity calculation methodology from HES images. (A) Demonstrates the workflow for the value of each pixel of the final cellularity
map from subregions measuring 500500 pixels in the HES slide (outlined by red lines). (B) Demonstrates our leave-two-out cross-validation process for optimizing
the luminosity threshold used in cellularity calculations via the use of a manually labeled test grid [red circles labeling nuclei in (B), bi]. The cross-validation score (CVS)
was used as a means to determine the accuracy of the technique (B), bii.
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FIGURE 3 | A flowchart of methodology for acquiring estimates of the fractional space occupied by lumina within histology images: k-means clustering of color
channels in the LAB image color space derived six classes from HES images, which were converted to binary and processed using morphological closing and region
labeling. For classes that identified the exterior of the lumina, the image-compliment was extracted; labeled areas above and below a threshold were discarded
(region selection). Identified areas from selected clusters were unified and the fraction of pixels occupied by lumina within pixel-regions represented a single pixel in
the final luminal fraction, -map.
Using 14 out of the 16 subregions, we then used a Leven-
berg–Marquardt algorithm to find the luminosity threshold that
minimized the sum of absolute differences between the cellularity
estimates for each subregion estimated using the above algorithm
and the reference gold-standard (Figure 2B, ii). The remaining
two subregions provided an unbiased estimate of the uncertainty
of the threshold (the cross-validation score, CVS). This process
was repeated eight times by leaving-out each combination of
neighboring subregions but ensuring a subregion was not re-used.
The final threshold used for the digitized slide was chosen as the
mean result from cross-validation and the CVS provided an esti-
mate on the uncertainty of the segmentation strategy (a median
uncertainty of within 9.42% with a range of 0.98% for the fifth
percentile to 42.16% for the 95th percentile across all samples).
3.2. Derivation of Luminal Fraction Maps
from Histology
Our methodology for extracting luminal fraction () maps from
histology is illustrated in Figure 3: images were converted from
the RGB into the Lab color space and an unsupervised K-means
clustering algorithm (k= 6) was applied on the color channels
(A and B). A subset of the segmented clusters was manually
selected and converted to binary. Morphological closing was
performed using a small disk-shaped structuring element and
spatially separate regions were identified using region labeling.
Any regionswhose size was deemed to be too small/large (e.g., due
to background noise) were discarded. Each pixel of the-mapwas
computed by calculating the fraction of pixels within each 20 20
pixel grid identified as luminal space in these images. Thismethod
was implemented in Matlab (Mathworks, Natick, MA, USA).
3.3. Simulation of Apparent Diffusion
Coefficient from Histology
We simulated the motion of water molecules within the diffusing
space derived from histology samples according to the method
outlined in Figure 4. Digitized images from HES slides were
divided into subregions, eachmeasuring 0.115mm 0.115mmto
represent a single pixel in the final sADCmap (resolutionmatched
to cellularity maps). Nuclei were segmented within each subre-
gion using the strategy detailed in the preceding section, which
provided a two-dimensional set,M(x; y) = M(x), of regions
in which the particles were allowed to freely diffuse. The random
trajectories of Np particles, with positions at time t denoted by
xti 2 R2, were simulated within the segmented diffusing space
over Nt time increments using the following algorithm:
t= 0
Uniformly sample x0i 2M
while t<Nt do
for i 2 Np do
xi  N (0; 2); 2 = 2Df TNt
if xti + xi 2M then
xt+1i  xti +xi
else
xt+1i  xti
end if
end for
t= t+ 1
end while
N (0; 2) represents a zero-centered Normal distribution with
isotropic covariance 2, Df is the diffusion coefficient of free
particles (set to 3.0 10 3 mm2/s to represent free water at 37°C)
and T is the total time particles are allowed to diffuse. If a particle
attempted to go past the edge of the image field-of-view, then
the subregion was tessellated to approximate an infinite spatial
field. The gradient of the mean-square-displacement curve of all
particles over the duration of the simulation time provided an
estimate of the simulated-diffusion coefficient of the particles
within each sub-region. In our experiment, we used Np= 5,000
and Nt= 2,630 (see Appendix A in Supplementary Material)
with the total diffusion-time, T= 8.67ms matched to that of our
DW-MRI protocol.
3.4. Animals and Ethics
Animal care and experiments were carried out in accordance
with Norwegian and EU guidelines for care and use of laboratory
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FIGURE 4 | An illustration of our methodology for deriving simulated-ADC (sADC) maps from segmented HES images using the following steps: (A) The original HES
image was divided into subregions measuring 500500 pixels (outlined in red). (B) For each subregion, the luminosity channel was derived from the original RGB
color space from which (C) nuclear boundaries were detected using our segmentation strategy (red outlines). (D) The trajectory of 10,000 diffusing particles was
simulated within the freely diffusing space over 1,000 time increments, each lasting 10 μs such that the total diffusion time matched that of our MRI experiment
(blue/green lines represent the trajectory of 100 of these particles). Where a boundary occurred, the subregion was tessellated to approximate an infinite spatial field.
(E) The gradient of the particle mean-square-displacement curve, over the duration of the simulation time provided an estimate of the simulated-diffusion coefficient
of the particles within the sub-region. (F) The sADC within each subregion provided a single pixel-value in the resulting sADC map.
animals and were approved by the Norwegian National Animal
Research Authority and the Norwegian Food Safety Authority
(FOTS application 3823). The colony of TRAMP mice used as
model organism in all animal experiments, were genetically mod-
ified from C57BL/6 mice (Jackson Labs, USA) and established in-
house (NTNU,Norway). Genotyping was performed by PCR. The
animals were kept in a standardized environment and monitored
for general health status and body weight for the duration of the
experiments.Male TRAMP (n= 9) and control (n= 6)mice from
the same genetic background (C57BL/6) were imaged using MRI
every 4weeks from 8weeks of age, and terminated at 28–30weeks
or when visual inspection of images indicated unacceptable tumor
burden. Mouse body weights were recorded before each MRI
session. In this study, results are presented from the final scanning
time point only, where parameters from MRI and histology were
compared.
3.5. Magnetic Resonance Imaging
MRI was performed on a 7T scanner (Biospec 70/20 Avance III,
Bruker Biospin MRI, Ettlingen, Germany) with a volume res-
onator (86mm diameter) for RF transmission and a phased array
mouse heart surface coil for reception. Mice were anesthetized
(2% isoflurane in medical air with 36% O2) for the duration of
the MRI scan and positioned on the scanner bed in a prone posi-
tion. Breathing motion in the pelvic region was reduced by firmly
securing themouse to the scanner bedwith adhesive tape across its
lower back. The respiration rate was monitored (SA Instruments,
USA), and the body temperature was maintained at 37°C by cir-
culating warm water through the bed. The followingMR-imaging
sequences were used: T2-weighted (T2W) images were acquired
in the axial plane with an isotropic in-plane resolution of 0.1mm
and slice thickness of 0.33mm using a RARE spin echo sequence
(TE= 36ms, TR= 5.5 s). Diffusion-weighted (DW-MRI) were
acquired over the same region of the mouse as T2W images
to allow for image registration; a fat-suppressed Stejskal–Tanner
prepared multi-shot EPI sequence was used with the follow-
ing parameters: TE= 28.5ms; TR= 3 s; b-values= 0, 100, 200,
400, 800 s/mm2 acquired along three orthogonal directions; aver-
ages= 4; matrix size= 128 128; slice thickness= 0.9mm; in-
plane resolution 0.2mm 0.2mm; number of EPI segments= 4.
ADC maps were calculated in Matlab (MathWorks, Natick, MA,
USA) by voxel-wise fitting of the signal (S) averaged over all gra-
dient directions using a monoexponential model for all b-values
according to:
S(b) = S(0)  e bADC
where S(0) is the signal intensity where b= 0 s/mm2. Regions of
interest (ROIs)were drawn byDKHonADCmaps around regions
corresponding to those drawn on histology. T2W and high-
resolution HES images were consulted to ensure corresponding
regions were chosen on ADC and cellularity maps.
3.6. Histology and Slide Digitization
Upon sacrifice, the genitourinary (GU) tract (prostate, seminal
vesicles, emptied bladder) was excised, weighed, and fixed in
formalin (10%) for at least 48 h. Samples were embedded such
that the sectioning plane was aligned with the MRI images, as
described in Ref. (34), and MR-images were used to identify
cancerous areas from which histology samples were acquired.
Formalin-fixed paraffin embedded samples were sectioned (4 μm
slice thickness) and stained with hematoxylin (ChemiTeknik AS,
Norway), erythrosine B (Sigma-Aldrich, Norway), and saffron
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FIGURE 5 | Representative images from C57BL/6, early stage cancer and advanced cancer TRAMP mice. Histology images were visually registered to
diffusion-weighted MR-images and corresponding regions of interest were drawn on both modalities. Cellularity and simulated-ADC (sADC) maps were derived from
histology images, while ADC maps were derived from MRI. Good registration was achieved and good correspondence between the histology derived sADC and
in vivo measured ADC was observed. PD, poorly differentiated adenocarcinoma.
(ChemiTeknik AS, Norway) using an automatic slide stainer
(Sakura Tissue-Tek© Prisma™). Whole HES-stained slides were
digitized into jpeg format using a Hamamatsu NanoZoomer
XR (Hamamatsu, Japan) scanner (40 magnification) such that
each pixel in the high-resolution digitized image had a square
resolution of 0.23 μm. Anatomopathological regions of interest
were highlighted on digital slides by a pathologist (Daniel N.
Rodrigues) using the tools provided by NanoZoomer Digital
Pathology (Hamamatsu, Japan). Benign areas were defined for
analysis on basis of predominant tissue type and included: fat,
smooth muscle, and benign glands. As the distinction between
intra-glandular overgrowth of luminal cells, i.e., prostatic intra-
epithelial neoplasm (PIN), and invasive gland-forming malignan-
cies, i.e., adenocarcinomas, occasionally depends on markers that
highlight micro-anatomical boundaries, PIN/adenocarcinoma
was considered as a single category. Overtly invasive tumors with
a solid growth pattern and complete absence of gland formation
were defined as poorly differentiated carcinomas.
4. RESULTS
Novel image analysis of digitized, whole-slide hematoxylin-eosin-
saffron (HES)-stained histology slides were used to generate three
quantitative maps of the microstructural properties in our mouse
prostate tissue samples: (i) tissue cellularity, (ii) luminal fraction,
and (iii) simulated-ADC (sADC). Figure 5 demonstrates exam-
ples of these maps from three of our samples; two from TRAMP
specimens and one from a healthy control (C57BL/6). Good
visual alignment between in vivo MRI and histology maps was
achieved by matching anatomical landmarks such as the urethra
and the different lobes of themouse prostate. This allowedmanual
delineation of anatomopathological regions of interest (ROIs) by
an experienced pathologist on (i) healthy prostate (from C57BL/6
mice), (ii) benign prostate (in TRAMP mice), (iii) adenocarci-
noma, and (iv) poorly differentiated disease; corresponding ROIs
were subsequently defined on MRI-derived ADC maps. Aver-
age values within these ROIs provided significant correlations
between these histology-derived structural maps and the MRI-
derived ADC maps as illustrated in Figure 6. Our model-fitting
strategy is presented in Appendix B in Supplementary Material.
4.1. Cellularity versus MR-Derived ADC
Figure 6A demonstrates the relationship between mean estimates
of MR-derived ADC and histology-derived cellularity (in units
of 103 cells/mm2) within the regions of interest defined on both
modalities. There is a significant inverse relationship between
ADC and tissue cellularity that is well described by our model
(equation (5)); we estimate the diffusion coefficient of the flu-
idic compartment of our model to be D0= 2.18 10 3 mm2/s
(95% CI: 1.90, 2.55), the average cross-sectional area of the non-
diffusing compartment to be An = 68:17 μm2 (59.52, 71.39) and
the tortuosity exponent to be  = 0.599 (0.597, 0.600). In addi-
tion to our model fitting approach, we performed a Leave-One-
Animal-Out (LOAO) cross validation of the data that revealed this
model was able to predict cellularity based on MR-derived ADC
estimates to within a median deviation of 34.5% (normalized-
root-mean-square-error= 0.18). This indicates that in this partic-
ular animalmodel, longitudinalmeasurements of ADC could pro-
vide a useful surrogate measurement of cellularity for monitoring
disease progression and/or treatment response. We also observe
a clear separation between normal and cancerous prostate tissue
by both parameters, and ROI clustering of different cancer grades,
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FIGURE 6 | Correspondence between MR-derived ADC with mean cellularity (A), mean luminal fraction (B), and mean simulated sADC (C) estimated from
whole-slide histology. Bold line represents the line of best fit of the model, as defined in the legend, the gray regions represent the 95% confidence intervals for the
line of best fit, and the dashed lines represent the 95% prediction confidence. Parameters from model fitting are provided in the figure legend, with 95% confidence
interval in parentheses.
providing evidence that ADC and cellularity serve as biomarkers
for disease aggressiveness in prostate cancer.
4.2. Fractional Luminal Space versus
MR-derived ADC
Figure 6B illustrates the significant positive correlation (r2= 0.49)
observed between average ADC and fractional space occupied by
prostate lumina within histology (as a percentage). A linear fit to
the slope provided a gradient of 16.3 (95% CI: 8.05, 24.55) with an
intercept of 3.33 (95%CI: 12.94, 6.29). LOAO cross-validation
analysis revealed this model was able to predict luminal space
based on MR-derived ADC estimates to within a median devia-
tion of 29.9% (normalized-root-mean-square-error= 0.20). This
demonstrates that ADC may also provide a suitable biomarker
for monitoring changes occurring to the glandular structure of
the prostate during the onset of disease and/or during treatment.
Luminal fraction also provided clear separation between poorly
differentiated and well differentiated adenocarcinoma, indicating
its utility for assessing tumor grade in the TRAMP model.
4.3. In silico Histology-Derived sADC
versus MR-Derived ADC
A plot of the average MR-derived ADC against sADC revealed
a significant linear trend (r2= 0.55) between both parameters
(Figure 6C). Linear fitting provided a gradient of 0.77 (95% CI:
0.42, 1.13) and intercept 1.29 (95%CI: 0.88, 1.70) indicating a pos-
itive bias in sADCcompared to conventional ADCmeasurements.
We attribute this bias to be a consequence of the assumption of free
diffusion (diffusion coefficient of 3.0 10 3 mm2/s for free water
at 37C) when simulating diffusion in histology images, ignoring
the presence of any cell membranes, organelles, and/or macro-
molecules in the extracellular space. These data demonstrate that
sADCmay serve as a useful surrogate for MR-derived ADC when
performing pixel-wise analysis of quantitative histology maps;
spatial registration between MRI and histology is known to be
problematic owing to a decrease in the size of histopathologic
specimens following fixation and slide preparation.
4.4. Pixel-Wise Relationships between
Structural Histology Metrics
Using sADC as a surrogate for in vivoMR-measurements of ADC
allowed us to consider pixel-wise relationships between all three
histologically derived parameters of prostate tissue morphology.
Scatter-plots of these parameters (Figure 7) suggest that there are
two principal linear compartments in these data; by performing
a 2-component linear mixture model (LMM), we derived maps
of the probability of each pixel on histology belonging to each of
these two compartments. One compartment (C1) was observed
to correspond to luminal epithelium, smooth muscle, and stroma,
while the other corresponded to the presence of luminal space
(C2). The linear relationships between sADC and cellularity in
both of these compartments were revealed to be similar (linear
gradient of 7.0 10 6 s/mm4 for C1 versus –8.2 10 6 s/mm4
for C2).
5. DISCUSSION
In this study, we present novel techniques to probe themicrostruc-
tural properties of healthy and diseased prostate from whole-
slide histology samples of a transgenic mouse model of prostate
cancer. This provides interpretation of the biological phenomena
occurring at a microscopic level that determine the apparent
diffusion coefficient measured at much larger length scales. Using
thesemethods, we provide direct evidence for a significant inverse
correlation between ADC and tissue cellularity.
We propose a compartmental model to relate MRI-derived
ADC with prostate tissue cellularity measured on whole-slide
histology. Our model consists of a non-diffusing compartment,
which we liken to water-impeding boundaries such as the cell
and nuclear walls, surrounded by a fluidic compartment, in which
diffusion can occur. From our data, the model predicts an average
area for the non-diffusing compartment of 68.17 μm2 (corre-
sponding to a circular radius of 4.66 μm). Our proposed model
further suggests that the relationship is non-linear, indicated by a
tortuosity exponent that was estimated to be significantly different
from 0.5 (p< 0.05). In addition, our model provides an estimate
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FIGURE 7 | Top-left: scatter-plot of sADC (in units of 10 3 mm2/s) versus luminal fraction (%) and cellularity (10 3 cells/mm2). Top-right: two components are
revealed through linear mixture modeling of these data; C1 and C2. Bottom: maps of the a posteriori class probability of histology reveals the spatial distribution of
these compartments: C1 originating from luminal epithelium, smooth muscle and stroma, and C2 originating from prostate lumina.
of the diffusion coefficient of the fluidic compartment to be lower
than that of free water at 37C (3.0 10 3 mm2/s). We attribute
this reduction in expectedADC to the presence of cellmembranes,
organelles in the cytoplasm, and macromolecules in the fluidic
compartment, which act to hinder the motion of water.
We also observe a significant correlation between ADC and
the proportion of space occupied by prostate lumina, indicat-
ing that the glandular structure of the prostate is an important
consideration when ascribing biological interpretation to mea-
sured differences in ADC, as recently suggested in the context
of T2-weighted MRI (38). This is also in accordance with pre-
vious findings in human prostate, where ADC was found to be
strongly associated with the percentage distribution of luminal
spaces (27).
Moving forward, current development in 3D-based
histopathology with optical tomography (39), and fiducial
markers to improve spatial co-registration of these modalities,
will allow further developments to the findings presented in this
study. The use of prostatectomy samples from human patients
would further justify the clinical utility of these techniques, as
the anatomical and histological appearance of TRAMP prostates
differs from human tissues (40). Supportive patient studies should
also include analysis at different clinical field-strengths (1.5 and
3.0T), where diffusion times may differ owing to the range of
gradient-sets used. The range of values of ADC, cellularity, and
luminal space reported in this study allowed us to differentiate
cancer severity and construct quantitative models that predict
cellularity and luminal space from ADC in this murine model
of prostate cancer. Should similar results be found in the clinic,
understanding these relationships may help clinicians interpret
findings from in vivo ADC measurements in prostate cancer and
relate them to the underlying tumor biology.
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The gold standard for diagnosing prostate cancer is by Glea-
son grading of multi-core transrectal ultrasound-guided prostate
(TRUS) biopsy (41). This invasive technique is prone to under-
sampling and underestimation of the grade (42) and does not
lend itself to serial measurements on the same tissue. Prelimi-
nary evidence suggests that multi-parametricMR-guided biopsies
improve prostate cancer detection over TRUS biopsy (43). Tech-
niques such as the ones developed in this study provide evidence
that MRI can be used as a non-invasive virtual biopsy to predict
the location and severity of prostatic disease through targeted tis-
sue sampling. This will spare patients from unnecessary invasive
procedures and reduce the risk of biopsy related complications
and disease misclassification.
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